Dr. Patrick Wilson

Prior exposure to one strain of influenza virus may weaken children’s ability to mount an effective antibody response against their subsequent exposure to a different flu strain, according to a study led by Weill Cornell Medicine investigators. 

Prior exposure to coronaviruses that cause ordinary colds can boost the immune system’s ability to attack a vulnerable site on the COVID-19-causing coronavirus SARS-CoV-2, according to a study led by investigators at Weill Cornell Medicine.

Along with an international team, Dr. John Moore, has brought biomedicine closer than ever to an HIV vaccine.

A team led by researchers at Weill Cornell Medicine, the University of Wisconsin-Madison; Scripps Research and the University of Chicago has identified an antibody that appears to block infection by all dominant variants of the virus that causes COVID-19, including omicron, the most recent.

A multi-institutional team of scientists, led by researchers at Weill Cornell Medicine’s Gale and Ira Drukier Institute for Children's Health, have received a five-year $8.297 grant to continue funding a Center for Lupus Research.

The scientists, whose results are published Dec. 23 in Nature, found that a small subset of antibodies elicited by experimental and existing influenza vaccines target a site at the base, or anchor, of the influenza virus hemagglutinin (HA) protein—an “epitope” whose significance was not recognized in prior influenza antibody studies.